The European Medicines Agency (EMA) is close to authorizing UCB's new treatment, Bimzelx, for hidradenitis suppurativa. The positive assessment from the Chmp suggests it could be...
It’s a billion-dollar biotech based out of California, and it has a host of late stage assets that are, assuming things run smoothly, poised to hit...